Early phase I study of non-viral CD19/CD22/BCMA tri-targeting JL-Lightning-CAR-T in relapsed/refractory B-cell non-Hodgkin's lymphoma.

Jinxing Lou(Shanghai University), Qijun Qian(Shanghai University), Qingping Zou(Shanghai Cell Therapy Research Institute), Lijie Rong(Shanghai Cell Therapy Research Institute), Hongfan Zhu(Shanghai Cancer Institute), Bin Wang(Hebei Medical University), Zhi‐Feng Miao(Kaohsiung Medical University), Shuya Wang(Central South University), Wenfeng Xu(Vyne Therapeutics (United States)), Zhicai Lin(Shanghai Cell Therapy Research Institute), Yan Sun(Shanghai University), Mengxin Xia(Shanghai University of Traditional Chinese Medicine), F. C. Ma(Shanghai Cell Therapy Research Institute), Xinhong Guan(Shanghai University)
Journal of Clinical Oncology
May 28, 2025
Cited by 0


Related Papers